Evidence map›Paper›PMID 30069312›Full record

ArticleJournal of thoracic disease2018

Neuregulin1 acts as a suppressor in human lung adenocarcinoma via AKT and ERK1/2 pathway.

Youya Wang, Zhifeng Ning, Xuefeng Zhou, Zetian Yang, Hexiao Tang, Ming Xu, Xianguo Wang, Jinping Zhao, Yuting Bai

Open access · hybridAbstract read
In one paragraph

Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Neuregulin 1 Gene (Cancers · 2021
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Youya WangDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhifeng NingBasic Medical School, Hubei University of Science and Technology, Xianning 437100, China.
Xuefeng ZhouDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zetian YangDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Hexiao TangDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Ming XuDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Xianguo WangDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Jinping ZhaoDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Yuting BaiDepartment of Cardiothoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhongnan Hospital of Wuhan University · CNWuhan University · CNHubei University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuregulin1 (NRG1) is critical signaling protein that mediates the activation of downstream signaling pathways associated with malignancies. Multiple gene fusions related to NRG1 have been found in lung cancer. However, the underlying role NRG1 in lung cancer is yet unclear. Therefore, the present study investigated the biological functions on human lung adenocarcinoma (LUAD).

methodsThe expression of NRG1 was detected in LUAD tissues by Western blot (WB), quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The expression of NRG1 was upregulated by the addition of exogenous NRG1 and downregulated by small interfering RNA (siRNA), and the biological behaviors of LUAD cells were assessed: cell proliferation by MTT assay, cell cycle and apoptosis by flow cytometry analysis, and migration and invasion using Transwell system. Finally, the pathway underlying the cellular function was analyzed by WB.

resultsA lower expression of NRG1 was observed in LUAD cancer tissues (P<0.05). Moreover, the addition of exogenous NRG1 reduced the cell proliferation, migration, and invasion (P<0.001), while the downregulation of endogenous NRG1 promoted the three kinds of biological behaviors of LUAD cell lines (P<0.001); however, these manifestations did no effect on the distribution of cell cycle and apoptosis status (P>0.05). Furthermore, the deficiency of NRG1 reduced the expression of p-ERK1/2 and p-AKT at the protein level (P<0.001).

conclusionsThe current results suggested that NRG1 might be a suppressor in the development of LUAD, and its function was related to AKT and ERK1/2 pathway.

Indexed as

AKTbiological behaviorinhibitionlung adenocarcinoma (LUAD)Neuregulin1 (NRG1)

Identifiers

PMID30069312
PMCPMC6051787
OpenAlexW2808405179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.